Camonsertib

Camonsertib is an investigational new drug that is being evaluated for the treatment of cancer. It is a selective oral small molecule inhibitor of ATR, developed by Repare Therapeutics. This drug targets tumors with specific genetic alterations that create vulnerabilities in DNA damage response pathways, particularly those with ATM or BRCA1/BRCA2 mutations. It is currently in Phase 2 clinical trials both as a monotherapy and in combination with other agents, including PARP inhibitors, gemcitabine, and lunresertib.